Angiotensin II and angiotensin-(1-7) inhibit the inner cortex Na+ -ATPase activity through AT2 receptor

Regul Pept. 2004 Aug 15;120(1-3):167-75. doi: 10.1016/j.regpep.2004.03.005.

Abstract

In the present paper, the modulation of the basolateral membrane (BLM) Na+ -ATPase activity of inner cortex from pig kidney by angiotensin II (Ang II) and angiotensin-(1-7) (Ang-(1-7)) was evaluated. Ang II and Ang-(1-7) inhibit the Na+ -ATPase activity in a dose-dependent manner (from 10(-11) to 10(-5) M), with maximal effect obtained at 10(-7) M for both peptides. Pharmacological evidences demonstrate that the inhibitory effects of Ang II and Ang-(1-7) are mediated by AT2 receptor: The effect of both polypeptides is completely reversed by 10(-8) M PD 123319, a selective AT2 receptor antagonist, but is not affected by either (10(-12) - 10(-5) M) losartan or (10(-10)-10(-7) M) A779, selective antagonists for AT1 and AT(1-7) receptors, respectively. The following results suggest that a PTX-insensitive, cholera toxin (CTX)-sensitive G protein/adenosine 3',5'-cyclic monophosphate (cAMP)/PKA pathway is involved in this process: (1) the inhibitory effect of both peptides is completely reversed by 10(-9) M guanosine 5'-O-(2-thiodiphosphate) (GDPbetaS; an inhibitor of the G protein activity), and mimicked by 10(-10) M guanosine 5'-O-(3-thiotriphosphate) (GTPgammaS; an activator of the G protein activity); (2) the effects of both peptides are mimicked by CTX but are not affected by PTX; (3) Western blot analysis reveals the presence of the Gs protein in the isolated basolateral membrane fraction; (4) (10(-10)-10(-6) M) cAMP has a similar and non-additive effect to Ang II and Ang-(1-7); (5) PKA inhibitory peptide abolishes the effects of Ang II and Ang-(1-7); and (6) both angiotensins stimulate PKA activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / pharmacology
  • Angiotensin I / pharmacology*
  • Angiotensin II / analogs & derivatives*
  • Angiotensin II / pharmacology*
  • Angiotensin II Type 1 Receptor Blockers / pharmacology
  • Angiotensin II Type 2 Receptor Blockers
  • Animals
  • Antihypertensive Agents / pharmacology*
  • Cholera Toxin / pharmacology
  • Cyclic AMP / metabolism
  • Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors
  • Cyclic AMP-Dependent Protein Kinases / metabolism
  • GTP-Binding Proteins / metabolism
  • Guanosine Diphosphate / metabolism
  • Guanosine Triphosphate / metabolism
  • Imidazoles / pharmacology
  • Kidney Cortex / drug effects*
  • Kidney Cortex / metabolism
  • Kidney Cortex / pathology
  • Losartan / pharmacology
  • Peptide Fragments / pharmacology*
  • Pertussis Toxin / pharmacology
  • Pyridines / pharmacology
  • Receptor, Angiotensin, Type 2 / agonists
  • Receptor, Angiotensin, Type 2 / metabolism*
  • Sodium-Potassium-Exchanging ATPase / metabolism*
  • Swine
  • Vasoconstrictor Agents / pharmacology*

Substances

  • 7-Ala-angiotensin (1-7)
  • Adjuvants, Immunologic
  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin II Type 2 Receptor Blockers
  • Antihypertensive Agents
  • Imidazoles
  • Peptide Fragments
  • Pyridines
  • Receptor, Angiotensin, Type 2
  • Vasoconstrictor Agents
  • Angiotensin II
  • PD 123319
  • Guanosine Diphosphate
  • Guanosine Triphosphate
  • Cholera Toxin
  • Angiotensin I
  • Cyclic AMP
  • Pertussis Toxin
  • Cyclic AMP-Dependent Protein Kinases
  • GTP-Binding Proteins
  • Sodium-Potassium-Exchanging ATPase
  • angiotensin I (1-7)
  • Losartan